- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05866640
Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
A Prospective, Single-Arm, Single Center Feasibility Trial to Evaluate the Safety and Performance of the F2 Filter and Delivery System Used for Embolic Protection During Transcatheter Aortic Valve Replacement
The goal of this clinical trial is to learn about the safety and performance of the F2 device for cerebral embolic protection in participants with symptomatic aortic stenosis underdoing a Transcatheter Aortic Valve replacement procedure.
Participants will complete several neurocognitive assessments and an MRI procedure.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Kathleen Calderon
- Phone Number: 307-250-2726
- Email: kcalderon@encompassf2.com
Study Contact Backup
- Name: Francis Duhay, MD
- Phone Number: 949-285-8170
- Email: FDuhay@encompassf2.com
Study Locations
-
-
-
Tbilisi, Georgia, 0112
- Recruiting
- Healthycore
-
Principal Investigator:
- Irakli Gogorishvili, MD
-
Contact:
- Irakli Gogorishvili, MD
- Phone Number: +995322433343
- Email: Gogorishvili@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
criteria:
- Age ≥ 22 years.
- The patient meets the established criteria and indications for commercially available TAVR (Edwards/Medtronic) for transfemoral access.
- Montreal Cognitive Assessment (MoCA) score ≥ 26 at screening.
- The patient is willing and able to comply with protocol-specified follow-up evaluations.
- The patient or legally authorized representative is able and willing to provide written informed consent.
Exclusion Criteria:
- Contraindications to MRI (e.g., subjects with MR unsafe implants including implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVR procedure, or claustrophobia).
- Severe peripheral arterial, abdominal aortic, or thoracic aortic disease that precludes delivery sheath vascular access or filter deployment.
- Patients in whom the aortic arch is heavily calcified, severely atheromatous, or severely tortuous.
- Ascending aortic diameter > 38 mm or transverse aortic diameter > 27 mm.
- Evidence of an acute myocardial infarction within 1 month before TAVR.
- Pre-existing prosthetic heart valve or prosthetic ring in any position.
- Known intracardiac thrombus.
- Severe allergy or known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel, nitinol, stainless steel alloy, and/or contrast sensitivity that cannot be adequately pre-medicated.
- History of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated.
- Patients who refuse blood transfusion.
- Active peptic ulcer or history of upper gastrointestinal (GI) bleeding within the prior 3 months.
- Recent (within 6 months) CVA or a TIA.
- Renal insufficiency (creatinine > 2.5 mg/dL or GFR < 30) and/or renal replacement therapy at the time of screening.
- Patients with hepatic failure (Child-Pugh class C).
- Patients with hypercoagulable states that cannot be corrected by additional periprocedural heparin.
- Patients presenting with cardiogenic shock or requiring vasopressor or inotropic support at the time of the index procedure.
- Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) < 20%.
- Life expectancy < 12 months.
- Currently participating in an investigational drug or another device study that has not completed the initial primary endpoint evaluation (e.g., long term follow-up study/continued access study subjects are able to be included).
- Subjects who have had treatment with any other investigational device within 30 days prior to study enrollment.
- Planned surgery or invasive procedure within 30 days following the index procedure (TAVR with F2 Filter).
- Patients planned to undergo any other cardiac surgical or interventional procedure (e.g., concurrent coronary revascularization) during the TAVR procedure or within 10 days prior to the TAVR procedure. NOTE: Balloon valvuloplasty during TAVR is permitted. Diagnostic cardiac catheterization is permitted within 10 days prior to the TAVR procedure.
- Patients with known mental or physical illness or known history of substance abuse that may cause non-compliance with the protocol or confound the data interpretation.
- Females who are pregnant or nursing or plan to become pregnant during their participation in the study. Female subjects of child-bearing potential must have a negative pregnancy test at screening.
Any other condition that in the opinion of the investigator, precludes study participation or poses a significant hazard to the patient.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Placement of the F2 device in the aorta to cover the great cerebral vessels.
|
Placement of F2 device in aorta to cover great cerebral vessels
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major adverse cardiac and cerebrovascular events
Time Frame: 30 days
|
Major adverse cardiac and cerebrovascular events
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
New lesions
Time Frame: 8-72 hours
|
total new lesion volume, average individual new lesion volume, number of new lesions, location of new lesions, territory of new lesions
|
8-72 hours
|
Performance
Time Frame: intra-procedure
|
technical success (% of patients with successful device deployment, position and retreival and procedure success (% of patients with technical device success and no device-related safety events)
|
intra-procedure
|
Modified Rankin Scale
Time Frame: 30 day
|
Measures neurological disability on scale of 0-6 (low score is better outcome)
|
30 day
|
National Institute of Health Stroke Scale
Time Frame: 30 day
|
Measures stroke severity on scale of 0 - 42 (low score is better outcome)
|
30 day
|
Montreal Cognitive Assessment
Time Frame: 30 day
|
Measures cognitive impairment on scale of 0 - 30 (high score is better outcome)
|
30 day
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Francis Duhay, MD, Sponsor GmbH
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RG01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Stenosis
-
Abbott Medical DevicesActive, not recruitingSevere Aortic Stenosis | Symptomatic Degenerative Aortic StenosisSpain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
-
Hospices Civils de LyonRecruiting
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Genesis Medtech CorporationRecruitingDiseases of Aortic Valve | Aortic Stenosis DiseaseChina
-
Saint Petersburg State University, RussiaNot yet recruitingIschemic Heart Disease | Mitral Insufficiency | Aortic Stenosis, Severe | Mitral Stenosis | Aortic Insufficiency | Ascending Aortic Aneurysm | Mitral Stenosis With Insufficiency | Tricuspid InsufficiencyRussian Federation
-
Pan XiangbinRecruiting
Clinical Trials on F2 filter and delivery system
-
EnCompass Technologies, Inc.RecruitingAortic StenosisAustralia
-
C. R. BardCompletedPulmonary Embolism | Venous Thromboembolic Disease
-
Lifetech Scientific (Shenzhen) Co., Ltd.Unknown
-
ShenZhen KYD Biomedical Technology Co., Ltd.Completed
-
Alcon ResearchCompleted
-
University of Missouri-ColumbiaTyco Healthcare GroupCompleted
-
W.L.Gore & AssociatesCompletedCardiovascular Diseases | Vascular Diseases | Cerebrovascular Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Arterial Occlusive Diseases | Pathological Conditions, Anatomical | Constriction, Pathologic | Carotid Stenosis | Carotid Artery DiseasesUnited States
-
Johns Hopkins UniversityWithdrawn
-
Masonic Cancer Center, University of MinnesotaOhio State UniversityWithdrawn